Junshi Biosciences Highlights Pipeline Advances in : vimarsana.com

--Favorable preliminary safety and efficacy data for anti-BTLA monoclonal antibody, icatolimab, for the treatment of lymphoma and solid tumors ...

Related Keywords

Guangzhou , Guangdong , China , Tongji , Sichuan , Shanghai , United States , Suzhou , Jiangsu , Beijing , Maryland , Peking , Canada , Jiaotong , Guizhou , Chicago , Illinois , San Francisco , California , Chinese , American , Russellj Schilder , Junshi Bioscience , Jie Wang , Jianjun Zou , Xinan Sheng , Jun Ma , Jun Zhu , Yiran Huang , Junshi Biosciences , Zhi Li , Jun Guo , American Society Of Clinical Oncology , Shanghai Jiaotong University School Of Medicine , Pr Team , Institute Of Microbiology The Chinese Academy , Harbin Institute Of Hematology Oncology , Global Research , Ir Team , University Cancer Hospital Institute , Tongji University , Thomas Jefferson University , National Reimbursement Drug List , National Cancer Center , National Medical Products Administration , Chinese Academy Of Medical Sciences , Shanghai Junshi Biosciences Co Ltd , Clinical Oncology , Annual Meeting , Development President , Professor Jun Zhu , Peking University Cancer Hospital , Harbin Institute , Professor Russell , Professor Jun Guo , Professor Yiran Huang , Ren Ji Hospital , Shanghai Jiaotong University School , Professor Ye Guo , Shanghai East Hospital , Progression Free Survival , Interim Overall Survival , Biomarker Analyses , Professor Jie Wang , Chinese Academy , Medical Sciences , New Drug Application , Southeast Asia , Breakthrough Therapy , Biologics License Application , Fast Track , Orphan Drug Designation , Emergency Use Authorizations , Hong Kong Stock Exchange 1877 Hk , Unshi Biosciences ,